IP Litigation Newsletter - April 2024

BakerHostetler
Contact

The safe harbor exception in 35 U.S.C. § 271(e)(1) applies “solely for uses reasonably related to the development and submission of information” to the Food and Drug Administration (FDA). The Federal Circuit interpreted the word “solely” as modifying “for uses,” finding that “for each act of infringement the safe harbor is available only for acts or uses that bear a reasonable relation to the development and submission of information to the FDA.” Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd., --- F.4th ---, 2024 WL 1243032 (Fed. Cir. Mar. 25, 2024) (Stoll, J., joined by Cunningham, J.). “It is not that the use must only be reasonably related to the development and submission of information to the FDA.” Dissenting, Judge Lourie stated, “I believe that ‘solely’ creates a safe harbor only for uses, sales, and importations that solely are for, as the statute says, development of information for the FDA.”

Please see full publication below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© BakerHostetler | Attorney Advertising

Written by:

BakerHostetler
Contact
more
less

BakerHostetler on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide